NCT00869089View on ClinicalTrials.gov

Safety and Efficacy of CC-10004 for Prurigo Nodularis

PHASE2CompletedINTERVENTIONAL

Enrollment

5

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions

Prurigo Nodularis

Interventions

DRUG

CC-10004

30mg,oral medication, BID, for 24 weeks (60mg total DAILY)

Trial Locations (1)

44106

University Hospitals Cleveland Medical Center, Cleveland

Sponsors

Collaborators (1)

Celgene Corporation

All Listed Sponsors

collaborator

Celgene Corporation

INDUSTRY

lead

University Hospitals Cleveland Medical Center

OTHER